- Shield Diagnostics, a producer of diagnostic kits for heart disease and syphilis, has announced fiscal 1995 pretax profits of L276,100 ($428,921) on a turnover of L5.8 million ($9.01 million), up 22%. Gross margins declined 5% from 48% due to the price increase of its syphilis products. The company invested L639,500 ($993,463) in R&D, a 43% rise on the previous year. As a result it is to launch seven additional products this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze